#MeToo | Vikas Bahl would hold me tight, smell my hair says Kangana

Mumbai, Jun 16: In the wake of Sushant Singh Rajput's death, veteran actor Deepti Naval has opened up about her struggle with depression and suicidal thoughts in the early 90s.

Naval shared a poem that she wrote during her struggle with depression on her Facebook page after paying tributes to Rajput, who was found hanging in his Bandra apartment on Sunday at the age of 34.

According to a police official, Mumbai Police found out during the probe that the actor was under medication for depression

"Dark days these... So much has been happening - mind has come to a point of stillness... Or rather numbness. Today I feel like sharing a poem I wrote back in the years when I was fighting depression, anxiety, suicidal thoughts - Yes, fighting... and like how," Naval wrote.

The 68-year-old actor made her debut with Shyam Benegal's 1978 "Junoon" and went on to feature in films like "Chashme Buddoor", "Ankahee", "Mirch Masala", Saath Saath among others in the 80s.

Naval's poem, titled "Black Wind", begins by describing how anxiety engulfs a person.

"Anxiety grips me with both hands, spiked claws dig deep into my soul I gasp for breath and stagger around sharp corners of my single bed.."

In the poem, Naval talks about fighting suicidal thoughts and depression, describing it as a "ghoulish lust" she won't succumb to.

"The telephone rings... no, it stops...God damn! Why don't anyone speak? A voice, Just a human voice In this shameless, pitiless Abyss of the night - gloom deepens into darkness, turns purple I feel dark inside."

The actor ends by writing that she will survive the night, its "deathly design" and fight.

"The world's a snake pit, so let it be! I dare the devil to get the better of me! Deepti Naval, Night of July 28, 1991."

In an interview with PTI last year, Naval had mentioned how acting assignments started to thin in the late 90s and as a "serious actor" it was "devastating" to be ignored.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

New Delhi, Jul 2: In the midst of India's tense border standoff with China, the defence ministry on Thursday approved procurement of a number of frontline fighter jets, missile systems and other platforms at a cost of Rs 38,900 crore to bolster the combat capability of the armed forces, officials said.

They said 21 MiG-29 fighter jets are being bought from Russia while 12 Su-30 MKI aircraft will be procured from Russia. The ministry has also approved a separate proposal to upgrade existing 59 MiG-29 aircraft.

The decisions were taken at a meeting of the Defence Acquisition Council (DAC) chaired by Defence Minister Rajnath Singh.

The procurement of 21 MiG-29 and upgrading of the existing fleet of MiG-29 are estimated to cost the government Rs 7,418 crore while purchase of 12 new Su-30 MKI from the Hindustan Aeronautics Ltd will be made at a cost of Rs 10,730 crore, the officials said.

The DAC also approved procurement of long-range land-attack cruise missile systems with a range of 1,000 KM and Astra Missiles for Navy and Air Force.

The officials said cost of these design and development proposals is in the range of Rs 20,400 crore.

"While acquisition of Pinaka missile systems will enable raising additional regiments over and above the ones already inducted, addition of long-range land attack missile systems having a firing range of 1000 KM to the existing arsenal will bolster the attack capabilities of the Navy and the Air Force," said a defence ministry official.

"Similarly induction of Astra Missiles having beyond visual range capability will serve as a force multiplier and immensely add to the strike capability of the Indian Navy and the Indian Air Force," he said.